Search
Search Results
-
Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives
CD30 is overexpressed in several lymphoma types, including classic Hodgkin lymphoma (cHL), some peripheral T-cell lymphomas (PTCL), and some...
-
CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma
T cell lymphomas (TCL) are heterogeneous, aggressive, and have few available targeted therapeutics. In this study, we determined that CD6, an...
-
Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy
Brentuximab vedotin (BV), CD30 specific antibody drug conjugate, has been used to treat anaplastic large cell lymphoma (ALCL) and classic Hodgkin...
-
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study
BackgroundMEDI7247 is a first-in-class antibody-drug conjugate (ADC) consisting of an anti-sodium-dependent alanine-serine-cysteine transporter 2...
-
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It...
-
A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers
Trophoblast cell surface antigen 2 (Trop2) is considered to be an attractive therapeutic target in cancer treatments. We previously generated a new...
-
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody-drug conjugates (ADCs) are a new class of monoclonal antibodies with the characteritic to specifically target tumor cells and to deliver a...
-
CD25-targeted antibody–drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma
Classic Hodgkin lymphoma (cHL) accounts for more than 90% of HL in developed countries. Although the current combined modality therapy make it have a...
-
Exploring the next generation of antibody–drug conjugates
Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to...
-
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
Purpose of ReviewOur review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in...
-
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
BackgroundLong-term outcome is unfavourable for relapsed/refractory (r/r) lymphoma patients who are resistant to salvage chemotherapy, even after...
-
Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance
AbstractAn antibody–drug conjugate (ADC) is an advanced chemotherapeutic option with immense promises in treating many tumor. They are designed to...
-
Specific ablation of PDGFRβ-overexpressing pericytes with antibody-drug conjugate potently inhibits pathologic ocular neovascularization in mouse models
BackgroundCrosstalk between pericytes and endothelial cells is critical for ocular neovascularization. Endothelial cells secrete platelet-derived...
-
Payload diversification: a key step in the development of antibody–drug conjugates
Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that currently combines the selectivity of monoclonal antibodies...
-
Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies
While most skin malignancies are successfully treated with surgical excision, advanced and metastatic skin malignancies still often have poor...
-
Antibody-drug conjugates in lung cancer: dawn of a new era?
Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in modern drug development. By harnessing the powers of both...
-
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned
Antibody–drug conjugates (ADCs) have emerged as a novel therapeutic strategy that has successfully reached patient treatment in different clinical...
-
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
Cancer is one of the leading causes of death worldwide due to high heterogeneity. Although chemotherapy remains the mainstay of cancer therapy,...
-
Antibody–drug conjugates—the magic bullet?
Antibody–drug conjugates (ADCs) are a relatively new class of highly potent molecules which combine the targeting properties of monoclonal antibodies...
-
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
Antibody–drug conjugates (ADCs), a class of targeted cancer therapeutics combining monoclonal antibodies with a cytotoxic payload via a chemical...
